EMLA reduces acute and chronic pain after breast surgery for cancer

Argyro Fassoulaki, Konstantinos D. Sarantopoulos, Aikaterini Melemeni, Quinn Hogan

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Background and Objectives: A significant percentage of women undergoing breast surgery for cancer may develop neuropathic pain in the chest, and/or ipsilateral axilla and/or upper medial arm, with impairment in performing daily occupational activities. We designed this study to determine if the perioperative application of EMLA (eutectic mixture of local anesthetics; AstraZeneca) cream in the breast and axilla area reduces analgesic requirements, as well as the acute and chronic pain after breast surgery. Methods: Forty-six female patients scheduled for breast surgery received randomly 5 g of EMLA or placebo on the sternal area 5 minutes before surgery, and 15 g on the supraclavicular area and axilla at the end of the operation. Treatment with EMLA cream (20 g) or placebo was also applied daily on the 4 days after surgery. In the postanesthesia care unit (PACU), 3, 6, 9, and 24 hours after surgery, and on the second to sixth day postoperatively, pain was assessed by visual analogue scale (VAS) at rest and after movement, and postoperative analgesic requirements were recorded. Three months later, patients were asked if they had pain in the chest wall, axilla and/or medial upper arm, decreased sensation, if they required analgesics at home, and for the intensity of pain. Results: Acute pain at rest and with movement did not differ between the EMLA and control groups, and the analgesics consumed during the first 24 hours were the same for the EMLA and control groups. However, time to the first analgesia requirement was longer (P = .04), and codeine and paracetamol consumption during the second to fifth days was less (P = .001, and P = .004, respectively) in the EMLA versus the control group. Three months postoperatively, pain in the chest wall, axilla, and the total incidence and the intensity of chronic pain were significantly less in the EMLA versus the control group (P = .004, P = .025, P = .002 and P = .003, respectively). The use of analgesics at home and abnormal sensations did not differ between the 2 groups. Conclusions: The application of EMLA to patients undergoing breast surgery for cancer reduced the postoperative analgesic requirements and the incidence and intensity of chronic pain.

Original languageEnglish
Pages (from-to)350-355
Number of pages6
JournalRegional Anesthesia and Pain Medicine
Volume25
Issue number4
DOIs
StatePublished - Jul 1 2000
Externally publishedYes

Fingerprint

Acute Pain
Chronic Pain
Breast Neoplasms
Axilla
Analgesics
Pain
Control Groups
Breast
Thoracic Wall
Arm
Placebos
EMLA
Codeine
Incidence
Neuralgia
Acetaminophen
Visual Analog Scale
Ambulatory Surgical Procedures
Analgesia
Thorax

Keywords

  • Local anesthetics: EMLA
  • Pain: acute, chronic
  • Surgery: breast, cancer

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

EMLA reduces acute and chronic pain after breast surgery for cancer. / Fassoulaki, Argyro; Sarantopoulos, Konstantinos D.; Melemeni, Aikaterini; Hogan, Quinn.

In: Regional Anesthesia and Pain Medicine, Vol. 25, No. 4, 01.07.2000, p. 350-355.

Research output: Contribution to journalArticle

Fassoulaki, Argyro ; Sarantopoulos, Konstantinos D. ; Melemeni, Aikaterini ; Hogan, Quinn. / EMLA reduces acute and chronic pain after breast surgery for cancer. In: Regional Anesthesia and Pain Medicine. 2000 ; Vol. 25, No. 4. pp. 350-355.
@article{5386fb742c4945fd850c78ee288a8fa4,
title = "EMLA reduces acute and chronic pain after breast surgery for cancer",
abstract = "Background and Objectives: A significant percentage of women undergoing breast surgery for cancer may develop neuropathic pain in the chest, and/or ipsilateral axilla and/or upper medial arm, with impairment in performing daily occupational activities. We designed this study to determine if the perioperative application of EMLA (eutectic mixture of local anesthetics; AstraZeneca) cream in the breast and axilla area reduces analgesic requirements, as well as the acute and chronic pain after breast surgery. Methods: Forty-six female patients scheduled for breast surgery received randomly 5 g of EMLA or placebo on the sternal area 5 minutes before surgery, and 15 g on the supraclavicular area and axilla at the end of the operation. Treatment with EMLA cream (20 g) or placebo was also applied daily on the 4 days after surgery. In the postanesthesia care unit (PACU), 3, 6, 9, and 24 hours after surgery, and on the second to sixth day postoperatively, pain was assessed by visual analogue scale (VAS) at rest and after movement, and postoperative analgesic requirements were recorded. Three months later, patients were asked if they had pain in the chest wall, axilla and/or medial upper arm, decreased sensation, if they required analgesics at home, and for the intensity of pain. Results: Acute pain at rest and with movement did not differ between the EMLA and control groups, and the analgesics consumed during the first 24 hours were the same for the EMLA and control groups. However, time to the first analgesia requirement was longer (P = .04), and codeine and paracetamol consumption during the second to fifth days was less (P = .001, and P = .004, respectively) in the EMLA versus the control group. Three months postoperatively, pain in the chest wall, axilla, and the total incidence and the intensity of chronic pain were significantly less in the EMLA versus the control group (P = .004, P = .025, P = .002 and P = .003, respectively). The use of analgesics at home and abnormal sensations did not differ between the 2 groups. Conclusions: The application of EMLA to patients undergoing breast surgery for cancer reduced the postoperative analgesic requirements and the incidence and intensity of chronic pain.",
keywords = "Local anesthetics: EMLA, Pain: acute, chronic, Surgery: breast, cancer",
author = "Argyro Fassoulaki and Sarantopoulos, {Konstantinos D.} and Aikaterini Melemeni and Quinn Hogan",
year = "2000",
month = "7",
day = "1",
doi = "10.1053/rapm.2000.7812",
language = "English",
volume = "25",
pages = "350--355",
journal = "Regional Anesthesia and Pain Medicine",
issn = "1098-7339",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - EMLA reduces acute and chronic pain after breast surgery for cancer

AU - Fassoulaki, Argyro

AU - Sarantopoulos, Konstantinos D.

AU - Melemeni, Aikaterini

AU - Hogan, Quinn

PY - 2000/7/1

Y1 - 2000/7/1

N2 - Background and Objectives: A significant percentage of women undergoing breast surgery for cancer may develop neuropathic pain in the chest, and/or ipsilateral axilla and/or upper medial arm, with impairment in performing daily occupational activities. We designed this study to determine if the perioperative application of EMLA (eutectic mixture of local anesthetics; AstraZeneca) cream in the breast and axilla area reduces analgesic requirements, as well as the acute and chronic pain after breast surgery. Methods: Forty-six female patients scheduled for breast surgery received randomly 5 g of EMLA or placebo on the sternal area 5 minutes before surgery, and 15 g on the supraclavicular area and axilla at the end of the operation. Treatment with EMLA cream (20 g) or placebo was also applied daily on the 4 days after surgery. In the postanesthesia care unit (PACU), 3, 6, 9, and 24 hours after surgery, and on the second to sixth day postoperatively, pain was assessed by visual analogue scale (VAS) at rest and after movement, and postoperative analgesic requirements were recorded. Three months later, patients were asked if they had pain in the chest wall, axilla and/or medial upper arm, decreased sensation, if they required analgesics at home, and for the intensity of pain. Results: Acute pain at rest and with movement did not differ between the EMLA and control groups, and the analgesics consumed during the first 24 hours were the same for the EMLA and control groups. However, time to the first analgesia requirement was longer (P = .04), and codeine and paracetamol consumption during the second to fifth days was less (P = .001, and P = .004, respectively) in the EMLA versus the control group. Three months postoperatively, pain in the chest wall, axilla, and the total incidence and the intensity of chronic pain were significantly less in the EMLA versus the control group (P = .004, P = .025, P = .002 and P = .003, respectively). The use of analgesics at home and abnormal sensations did not differ between the 2 groups. Conclusions: The application of EMLA to patients undergoing breast surgery for cancer reduced the postoperative analgesic requirements and the incidence and intensity of chronic pain.

AB - Background and Objectives: A significant percentage of women undergoing breast surgery for cancer may develop neuropathic pain in the chest, and/or ipsilateral axilla and/or upper medial arm, with impairment in performing daily occupational activities. We designed this study to determine if the perioperative application of EMLA (eutectic mixture of local anesthetics; AstraZeneca) cream in the breast and axilla area reduces analgesic requirements, as well as the acute and chronic pain after breast surgery. Methods: Forty-six female patients scheduled for breast surgery received randomly 5 g of EMLA or placebo on the sternal area 5 minutes before surgery, and 15 g on the supraclavicular area and axilla at the end of the operation. Treatment with EMLA cream (20 g) or placebo was also applied daily on the 4 days after surgery. In the postanesthesia care unit (PACU), 3, 6, 9, and 24 hours after surgery, and on the second to sixth day postoperatively, pain was assessed by visual analogue scale (VAS) at rest and after movement, and postoperative analgesic requirements were recorded. Three months later, patients were asked if they had pain in the chest wall, axilla and/or medial upper arm, decreased sensation, if they required analgesics at home, and for the intensity of pain. Results: Acute pain at rest and with movement did not differ between the EMLA and control groups, and the analgesics consumed during the first 24 hours were the same for the EMLA and control groups. However, time to the first analgesia requirement was longer (P = .04), and codeine and paracetamol consumption during the second to fifth days was less (P = .001, and P = .004, respectively) in the EMLA versus the control group. Three months postoperatively, pain in the chest wall, axilla, and the total incidence and the intensity of chronic pain were significantly less in the EMLA versus the control group (P = .004, P = .025, P = .002 and P = .003, respectively). The use of analgesics at home and abnormal sensations did not differ between the 2 groups. Conclusions: The application of EMLA to patients undergoing breast surgery for cancer reduced the postoperative analgesic requirements and the incidence and intensity of chronic pain.

KW - Local anesthetics: EMLA

KW - Pain: acute, chronic

KW - Surgery: breast, cancer

UR - http://www.scopus.com/inward/record.url?scp=0034235007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034235007&partnerID=8YFLogxK

U2 - 10.1053/rapm.2000.7812

DO - 10.1053/rapm.2000.7812

M3 - Article

C2 - 10925929

AN - SCOPUS:0034235007

VL - 25

SP - 350

EP - 355

JO - Regional Anesthesia and Pain Medicine

JF - Regional Anesthesia and Pain Medicine

SN - 1098-7339

IS - 4

ER -